Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its price objective increased by Royal Bank Of Canada from $296.00 to $305.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the specialty pharmaceutical company’s stock.
A number of other research firms also recently commented on JAZZ. Barclays lifted their target price on Jazz Pharmaceuticals from $270.00 to $271.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $337.00 price objective on the stock. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, August 4th. Finally, Canaccord Genuity Group set a $300.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $293.45.
Check Out Our Latest Research Report on JAZZ
Jazz Pharmaceuticals Trading Down 3.1%
Shares of JAZZ opened at $227.32 on Tuesday. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09. The firm has a 50-day moving average price of $229.71 and a 200 day moving average price of $217.40. Jazz Pharmaceuticals has a 12-month low of $128.80 and a 12-month high of $266.38. The firm has a market capitalization of $14.59 billion, a P/E ratio of 20.80, a P/E/G ratio of 0.47 and a beta of 0.38.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating the consensus estimate of ($4.03) by $0.15. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $8.13 EPS. Sell-side analysts forecast that Jazz Pharmaceuticals will post 10.84 EPS for the current year.
Insider Activity
In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 76,921 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the sale, the executive vice president directly owned 65,686 shares of the company’s stock, valued at approximately $16,401,794.20. This represents a 53.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $236.40, for a total transaction of $472,800.00. Following the sale, the chief executive officer directly owned 141,394 shares of the company’s stock, valued at approximately $33,425,541.60. This trade represents a 1.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 101,121 shares of company stock worth $24,858,332 over the last three months. Insiders own 4.10% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. USA Financial Formulas acquired a new position in Jazz Pharmaceuticals in the 1st quarter valued at $25,000. Pension & Wealth Management Advisors Inc. purchased a new position in Jazz Pharmaceuticals during the 3rd quarter worth $32,000. Ameritas Advisory Services LLC purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth $47,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth $61,000. Finally, Elevation Wealth Partners LLC lifted its stake in shares of Jazz Pharmaceuticals by 156.4% in the 3rd quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock worth $60,000 after acquiring an additional 158 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.
Key Jazz Pharmaceuticals News
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
- Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
- Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Featured Articles
- Five stocks we like better than Jazz Pharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
